Myriad Genetics (MYGN) stock price, revenue, and financials

Myriad Genetics market cap is $945.8 m, and annual revenue was $638.60 m in FY 2020

$945.8 M

MYGN Mkt cap, 22-Sept-2020

$638.6 M

Myriad Genetics Revenue FY, 2020
Myriad Genetics Net income (FY, 2020)-199.6 M
Myriad Genetics EBIT (FY, 2020)-231.7 M
Myriad Genetics Cash, 30-Jun-2020163.7 M
Myriad Genetics EV1.1 B

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing

Myriad Genetics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

771.4m772.6m851.1m638.6m

Revenue growth, %

4%0%10%

Cost of goods sold

171.2m177.2m201.0m

Gross profit

600.2m595.4m650.1m

Gross profit Margin, %

78%77%76%

R&D expense

74.4m70.8m85.9m77.2m

General and administrative expense

476.4m467.1m555.5m510.1m

Operating expense total

550.0m476.7m641.4m687.0m

EBIT

49.4m118.7m7.6m(231.7m)

EBIT margin, %

6%15%1%(36%)

Interest expense

6.0m3.2m12.0m

Interest income

1.2m1.8m3.2m

Pre tax profit

42.9m116.9m(223.3m)

Income tax expense

21.3m(14.0m)(4.4m)(23.7m)

Net Income

21.6m130.9m4.4m(199.6m)

EPS

0.31.80.1

Myriad Genetics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.4m110.9m93.2m163.7m

Accounts Receivable

105.6m98.3m133.9m68.1m

Prepaid Expenses

12.7m9.4m16.6m

Inventories

42.2m34.3m31.4m29.1m

Current Assets

317.1m326.4m348.6m331.7m

PP&E

51.1m43.2m57.3m143.9m

Goodwill

316.1m318.6m417.2m327.6m

Total Assets

1.2b1.2b1.6b1.4b

Accounts Payable

22.0m26.0m33.3m21.7m

Short-term debt

127.3m5.3m3.4m13.5m

Current Liabilities

217.5m102.2m117.8m

Long-term debt

112.3m18.5m243.9m281.3m

Total Debt

239.6m23.8m247.3m294.8m

Total Liabilities

446.6m209.2m473.8m486.4m

Common Stock

700.0k700.0k700.0k700.0k

Additional Paid-in Capital

851.4m915.4m1.1b1.1b

Retained Earnings

(68.4m)52.9m25.6m(173.9m)

Total Equity

777.8m964.9m1.1b918.2m

Debt to Equity Ratio

0.3 x0 x0.2 x

Debt to Assets Ratio

0.2 x0 x0.2 x

Financial Leverage

1.6 x1.2 x1.4 x1.5 x

Myriad Genetics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

21.8m131.1m4.6m(199.5m)

Depreciation and Amortization

48.3m54.4m73.0m

Accounts Receivable

(41.4m)(39.2m)(18.2m)600.0k

Inventories

(1.2m)7.9m8.0m1.6m

Accounts Payable

(3.0m)4.0m1.1m(10.7m)

Cash From Operating Activities

106.2m115.9m83.7m60.7m

Purchases of PP&E

(6.1m)(8.4m)(8.6m)(10.2m)

Cash From Investing Activities

(146.3m)(11.6m)(286.4m)19.3m

Short-term Borrowings

(8.6m)

Long-term Borrowings

(305.0m)(185.4m)(115.0m)

Cash From Financing Activities

71.8m(95.0m)182.3m

Net Change in Cash

33.9m8.5m(17.7m)70.5m

Myriad Genetics Ratios

USDFY, 2017

Revenue/Employee

321.4k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.6 x

Myriad Genetics Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019FY, 2019Mar, 2020

Patients Tested to Date

2 m3 m3 m

Products

11

Publications to Date

1 k

Countries

143

Commercial Payers (Prolaris)

8 9

Commercial Lives Under Coverage (Prolaris)

20 m24 m

Trademarks

67

Myriad Genetics Employee Rating

3.6250 votes
Culture & Values
3.8
Work/Life Balance
4.1
Senior Management
3.3
Salary & Benefits
3.5
Career Opportunities
3.1
Source